Carlos S Moreno
Overview
Explore the profile of Carlos S Moreno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
3427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibbs D, McCrary M, Moreno C, Seldin L, Li C, Kamili N, et al.
BMC Genomics
. 2025 Feb;
26(1):122.
PMID: 39924511
Background: Epidermal growth factor receptor inhibitors (EGFRIs) are used to treat certain cancers but frequently cause cutaneous inflammation that can hinder treatment. This is due in part to the effects...
2.
Moreno C, Winham C, Alemozaffar M, Klein E, Lawal I, Abiodun-Ojo O, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067373
Prostate cancer is a highly heterogeneous disease and mortality is mainly due to metastases but the initial steps of metastasis have not been well characterized. We have performed integrative whole...
3.
Camargo A, Constantino F, Santos S, Colombelli K, Portela L, Fioretto M, et al.
Mol Cell Endocrinol
. 2023 Nov;
580:112102.
PMID: 37972683
The developmental Origins of Health and Disease (DOHaD) concept has provided the framework to assess how early life experiences can shape health and disease throughout the life course. Using a...
4.
Portela L, Constantino F, Camargo A, Santos S, Colombelli K, Fioretto M, et al.
Sci Rep
. 2023 Nov;
13(1):18685.
PMID: 37907720
The Developmental Origins of Health and Disease (DOHaD) concept has provided the framework to assess how early life experiences can shape health and disease throughout the life course. While maternal...
5.
Zeng L, Zhu Y, Moreno C, Wan Y
Semin Cancer Biol
. 2023 Feb;
90:29-44.
PMID: 36806560
Despite the development of cancer therapies, the success of most treatments has been impeded by drug resistance. The crucial role of tumor cell plasticity has emerged recently in cancer progression,...
6.
Boya M, Ozkaya-Ahmadov T, Swain B, Chu C, Asmare N, Civelekoglu O, et al.
Nat Commun
. 2022 Jun;
13(1):3385.
PMID: 35697674
Extremely rare circulating tumor cell (CTC) clusters are both increasingly appreciated as highly metastatic precursors and virtually unexplored. Technologies are primarily designed to detect single CTCs and often fail to...
7.
Mo X, Niu Q, Ivanov A, Tsang Y, Tang C, Shu C, et al.
Cell
. 2022 May;
185(11):1974-1985.e12.
PMID: 35512704
Comprehensive sequencing of patient tumors reveals genomic mutations across tumor types that enable tumorigenesis and progression. A subset of oncogenic driver mutations results in neomorphic activity where the mutant protein...
8.
Ouellet V, Erickson A, Wiley K, Morrissey C, Berge V, Moreno C, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Feb;
31(4):715-727.
PMID: 35131885
Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember....
9.
Su K, Yu Q, Shen R, Sun S, Moreno C, Li X, et al.
Cell Rep Methods
. 2021 Oct;
1(4).
PMID: 34671755
Identifying biomarkers to predict the clinical outcomes of individual patients is a fundamental problem in clinical oncology. Multiple single-gene biomarkers have already been identified and used in clinics. However, multiple...
10.
Roback J, Tyburski E, Alter D, Asakrah S, Chahroudi A, Esper A, et al.
Nat Biotechnol
. 2021 Aug;
39(9):1060-1062.
PMID: 34404954
No abstract available.